Cognitive disorder
Rare disease
No
- Definition
- A disease affects cognitive processes.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Cognitive disorder
- cognitive disorder
- Cognitive Diseases
- Cognitive Dysfunction, Cognitive Disorder
- Mild Cognitive Disorder
- Mild Cognitive Disorder (Vascular)
- Severity
- Unknown
- MONDO ID
- MONDO:0002039
- Parent condition
- MONDO:0002025
Related records
Broader conditions (4)
- Disease
- Disease by developmental or physiological process
- Human disease
- Psychiatric disorder
Narrower conditions (203)
- Aceruloplasminemia
- Adrenoleukodystrophy
- Adrenomyeloneuropathy
- AIDS dementia complex
- Alcohol amnestic disorder
- Alcohol-induced Wernicke-Korsakoff's syndrome
- Alcoholic psychosis
- Alexia
- Alzheimer disease
- Alzheimer disease 10
- Alzheimer disease 11
- Alzheimer disease 12
- Alzheimer disease 13
- Alzheimer disease 14
- Alzheimer disease 16
- Alzheimer disease 17
- Alzheimer disease 18
- Alzheimer disease 19
- Alzheimer disease 2
- Alzheimer disease 3
Trials (5,043)
- "Cognitive Rehabilitation With Direct Current Transcranial Stimulation in Post-Traumatic Brain Injury Patients"
- "LiverColor": Machine Learning in Liver Photographs
- "Pregnancy and Viral Infections: Impact on Pregnant Women and Their Children. French Prospective Cohort"
- (MAP) Pilot Randomized Controlled Trial for Older Adults With Mild Cognitive Impairment and Elevated Stress
- (Neuro)Cognitive Remediation for Adults With OSIs
- [11C]PS13 PET Imaging of Neuroinflammation in Heart Failure With Reduced Ejection Fraction
- [18F]MC225-PET in Neurodegenerative Disease
- [18F]THK-5351 Positron Emission Computed Tomography Study of Normal, Mild Cognitive Impairment, Alzheimer's Disease and Other Neurodegenerative Disease
- 1-hour Post-load Hyperglycemia and Mild Cognitive Impairment
- 1/2-Dopaminergic Dysfunction in Late-Life Depression (The D3 Study)
- 100-Year Human Aging Study
- 11C-Acetate PET/CT Imaging As a Biomarker of Amyloid-Induced Neuroinflammation
- 11C-PIB PET Study in MESA at Columbia University
- 11C-PIB PET/CT in Patients With Parkinson's Disease and Parkinsonian Dementia Syndromes
- 12-week Tele-exercise Program in Patients With OSA
- 18-Month Study of Memory Effects of Curcumin
- 18F-AV-1451 PET Imaging in Participants Enrolled in the LEARN Study
- 18F-DPA-714 PET/MR in Dysfunctional Brain Diseases
- 18F-FDG PET/CT in Diagnostic Patients of Disorder of Consciousness
- 2-Hydroxybenzylamine (2-HOBA) Study in Early Alzheimer's Patients
Drugs in development (36)
- (D)-serine Phase 1
- ABT-126 Phase 2
- Armodafinil Phase 2
- Ascorbic acid Phase 3
- Bifidobacterium SPP. Phase 3
- Deferiprone Phase 1
- Dihydrexidine Phase 1
- Donepezil Phase 2
- Emoxypine succinate Phase 3
- Gonadorelin acetate Phase 2
- HTL-9936 Phase 1
- Hydrocortisone Phase 1
- Iclepertin Phase 1
- Insulin human Phase 2
- Ispronicline Phase 2
- Ketamine Phase 1
- Lamotrigine Phase 1
- Lovastatin Phase 2
- Maraviroc Phase 2
- Memantine Phase 3
Other linked drugs (13)
- Budesonide
- Cycloserine
- Darbepoetin alfa
- Desflurane
- Epoetin alfa
- Epoetin beta
- Ginkgo
- Glycine
- Metformin
- Pergolide
- Pergolide mesylate
- Propofol
- Sarizotan